Predictors of asthma control in everyday clinical practice in Switzerland

Anne B Taegtmeyer, C Steurer-Stey, David B Price, J H Wildhaber, F Spertini, Jörg D Leuppi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

OBJECTIVE: To identify predictors of improved asthma control under conditions of everyday practice in Switzerland. RESEARCH DESIGN AND METHODS: A subgroup of 1380 patients with initially inadequately controlled asthma was defined from a cohort of 1893 asthmatic patients (mean age 45.3 + or - 19.2 years) recruited by 281 office-based physicians who participated in a previously-conducted asthma control survey in Switzerland. Multiple regression techniques were used to identify predictors of improved asthma control, defined as an absolute decrease of 0.5 points or more in the Asthma Control Questionnaire between the baseline (V1) and follow-up visit (V2). RESULTS: Asthma control between V1 and V2 improved in 85.7%. Add-on treatment with montelukast was reported in 82.9% of the patients. Patients with worse asthma control at V1 and patients with good self-reported adherence to therapy had significantly higher chances of improved asthma control (OR = 1.24 and 1.73, 95% CI 1.18-1.29 and 1.20-2.50, respectively). Compared to adding montelukast and continuing the same inhaled corticosteroid/fixed combination (ICS/FC) dose, the addition of montelukast to an increased ICS/FC dose yielded a 4 times higher chance of improved asthma control (OR = 3.84, 95% CI 1.58-9.29). Significantly, withholding montelukast halved the probability of achieving improved asthma control (OR = 0.51, 95% CI = 0.33-078). The probability of improved asthma control was almost 5 times lower among patients in whom FEV(1) was measured compared to those in whom it was not (OR = 0.23, 95% CI = 0.09-0.55). Patients with severe persistent asthma also had a significantly lower probability of improved control (OR = 0.15, 95% CI = 0.07-0.32), as did older patients (OR = 0.98, 95% CI = 0.97-0.99). Subgroup analyses which excluded patients whose asthma may have been misdiagnosed and might in reality have been chronic obstructive pulmonary disease (COPD) showed comparable results. CONCLUSIONS: Under conditions of everyday clinical practice, the addition of montelukast to ICS/FC and good adherence to therapy increased the likelihood of achieving better asthma control at the follow-up visit, while older age and more severe asthma significantly decreased it.
Original languageEnglish
Pages (from-to)2549-2555
Number of pages7
JournalCurrent Medical Research and Opinion
Volume25
Issue number10
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Switzerland
montelukast
Asthma
Adrenal Cortex Hormones
Nijmegen Breakage Syndrome
Physicians' Offices
Diagnostic Errors
Chronic Obstructive Pulmonary Disease
Research Design
Therapeutics

Keywords

  • acetates
  • adult
  • anti-asthmatic agents
  • asthma
  • cohort studies
  • female
  • humans
  • male
  • middle aged
  • quinolines
  • Switzerland

Cite this

Taegtmeyer, A. B., Steurer-Stey, C., Price, D. B., Wildhaber, J. H., Spertini, F., & Leuppi, J. D. (2009). Predictors of asthma control in everyday clinical practice in Switzerland. Current Medical Research and Opinion, 25(10), 2549-2555. https://doi.org/10.1185/03007990903224125

Predictors of asthma control in everyday clinical practice in Switzerland. / Taegtmeyer, Anne B; Steurer-Stey, C; Price, David B; Wildhaber, J H; Spertini, F; Leuppi, Jörg D.

In: Current Medical Research and Opinion, Vol. 25, No. 10, 10.2009, p. 2549-2555.

Research output: Contribution to journalArticle

Taegtmeyer, AB, Steurer-Stey, C, Price, DB, Wildhaber, JH, Spertini, F & Leuppi, JD 2009, 'Predictors of asthma control in everyday clinical practice in Switzerland' Current Medical Research and Opinion, vol. 25, no. 10, pp. 2549-2555. https://doi.org/10.1185/03007990903224125
Taegtmeyer, Anne B ; Steurer-Stey, C ; Price, David B ; Wildhaber, J H ; Spertini, F ; Leuppi, Jörg D. / Predictors of asthma control in everyday clinical practice in Switzerland. In: Current Medical Research and Opinion. 2009 ; Vol. 25, No. 10. pp. 2549-2555.
@article{bcc02ca225884bbdb4aeb2940331fc92,
title = "Predictors of asthma control in everyday clinical practice in Switzerland",
abstract = "OBJECTIVE: To identify predictors of improved asthma control under conditions of everyday practice in Switzerland. RESEARCH DESIGN AND METHODS: A subgroup of 1380 patients with initially inadequately controlled asthma was defined from a cohort of 1893 asthmatic patients (mean age 45.3 + or - 19.2 years) recruited by 281 office-based physicians who participated in a previously-conducted asthma control survey in Switzerland. Multiple regression techniques were used to identify predictors of improved asthma control, defined as an absolute decrease of 0.5 points or more in the Asthma Control Questionnaire between the baseline (V1) and follow-up visit (V2). RESULTS: Asthma control between V1 and V2 improved in 85.7{\%}. Add-on treatment with montelukast was reported in 82.9{\%} of the patients. Patients with worse asthma control at V1 and patients with good self-reported adherence to therapy had significantly higher chances of improved asthma control (OR = 1.24 and 1.73, 95{\%} CI 1.18-1.29 and 1.20-2.50, respectively). Compared to adding montelukast and continuing the same inhaled corticosteroid/fixed combination (ICS/FC) dose, the addition of montelukast to an increased ICS/FC dose yielded a 4 times higher chance of improved asthma control (OR = 3.84, 95{\%} CI 1.58-9.29). Significantly, withholding montelukast halved the probability of achieving improved asthma control (OR = 0.51, 95{\%} CI = 0.33-078). The probability of improved asthma control was almost 5 times lower among patients in whom FEV(1) was measured compared to those in whom it was not (OR = 0.23, 95{\%} CI = 0.09-0.55). Patients with severe persistent asthma also had a significantly lower probability of improved control (OR = 0.15, 95{\%} CI = 0.07-0.32), as did older patients (OR = 0.98, 95{\%} CI = 0.97-0.99). Subgroup analyses which excluded patients whose asthma may have been misdiagnosed and might in reality have been chronic obstructive pulmonary disease (COPD) showed comparable results. CONCLUSIONS: Under conditions of everyday clinical practice, the addition of montelukast to ICS/FC and good adherence to therapy increased the likelihood of achieving better asthma control at the follow-up visit, while older age and more severe asthma significantly decreased it.",
keywords = "acetates, adult, anti-asthmatic agents, asthma, cohort studies, female, humans, male, middle aged, quinolines, Switzerland",
author = "Taegtmeyer, {Anne B} and C Steurer-Stey and Price, {David B} and Wildhaber, {J H} and F Spertini and Leuppi, {J{\"o}rg D}",
year = "2009",
month = "10",
doi = "10.1185/03007990903224125",
language = "English",
volume = "25",
pages = "2549--2555",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Predictors of asthma control in everyday clinical practice in Switzerland

AU - Taegtmeyer, Anne B

AU - Steurer-Stey, C

AU - Price, David B

AU - Wildhaber, J H

AU - Spertini, F

AU - Leuppi, Jörg D

PY - 2009/10

Y1 - 2009/10

N2 - OBJECTIVE: To identify predictors of improved asthma control under conditions of everyday practice in Switzerland. RESEARCH DESIGN AND METHODS: A subgroup of 1380 patients with initially inadequately controlled asthma was defined from a cohort of 1893 asthmatic patients (mean age 45.3 + or - 19.2 years) recruited by 281 office-based physicians who participated in a previously-conducted asthma control survey in Switzerland. Multiple regression techniques were used to identify predictors of improved asthma control, defined as an absolute decrease of 0.5 points or more in the Asthma Control Questionnaire between the baseline (V1) and follow-up visit (V2). RESULTS: Asthma control between V1 and V2 improved in 85.7%. Add-on treatment with montelukast was reported in 82.9% of the patients. Patients with worse asthma control at V1 and patients with good self-reported adherence to therapy had significantly higher chances of improved asthma control (OR = 1.24 and 1.73, 95% CI 1.18-1.29 and 1.20-2.50, respectively). Compared to adding montelukast and continuing the same inhaled corticosteroid/fixed combination (ICS/FC) dose, the addition of montelukast to an increased ICS/FC dose yielded a 4 times higher chance of improved asthma control (OR = 3.84, 95% CI 1.58-9.29). Significantly, withholding montelukast halved the probability of achieving improved asthma control (OR = 0.51, 95% CI = 0.33-078). The probability of improved asthma control was almost 5 times lower among patients in whom FEV(1) was measured compared to those in whom it was not (OR = 0.23, 95% CI = 0.09-0.55). Patients with severe persistent asthma also had a significantly lower probability of improved control (OR = 0.15, 95% CI = 0.07-0.32), as did older patients (OR = 0.98, 95% CI = 0.97-0.99). Subgroup analyses which excluded patients whose asthma may have been misdiagnosed and might in reality have been chronic obstructive pulmonary disease (COPD) showed comparable results. CONCLUSIONS: Under conditions of everyday clinical practice, the addition of montelukast to ICS/FC and good adherence to therapy increased the likelihood of achieving better asthma control at the follow-up visit, while older age and more severe asthma significantly decreased it.

AB - OBJECTIVE: To identify predictors of improved asthma control under conditions of everyday practice in Switzerland. RESEARCH DESIGN AND METHODS: A subgroup of 1380 patients with initially inadequately controlled asthma was defined from a cohort of 1893 asthmatic patients (mean age 45.3 + or - 19.2 years) recruited by 281 office-based physicians who participated in a previously-conducted asthma control survey in Switzerland. Multiple regression techniques were used to identify predictors of improved asthma control, defined as an absolute decrease of 0.5 points or more in the Asthma Control Questionnaire between the baseline (V1) and follow-up visit (V2). RESULTS: Asthma control between V1 and V2 improved in 85.7%. Add-on treatment with montelukast was reported in 82.9% of the patients. Patients with worse asthma control at V1 and patients with good self-reported adherence to therapy had significantly higher chances of improved asthma control (OR = 1.24 and 1.73, 95% CI 1.18-1.29 and 1.20-2.50, respectively). Compared to adding montelukast and continuing the same inhaled corticosteroid/fixed combination (ICS/FC) dose, the addition of montelukast to an increased ICS/FC dose yielded a 4 times higher chance of improved asthma control (OR = 3.84, 95% CI 1.58-9.29). Significantly, withholding montelukast halved the probability of achieving improved asthma control (OR = 0.51, 95% CI = 0.33-078). The probability of improved asthma control was almost 5 times lower among patients in whom FEV(1) was measured compared to those in whom it was not (OR = 0.23, 95% CI = 0.09-0.55). Patients with severe persistent asthma also had a significantly lower probability of improved control (OR = 0.15, 95% CI = 0.07-0.32), as did older patients (OR = 0.98, 95% CI = 0.97-0.99). Subgroup analyses which excluded patients whose asthma may have been misdiagnosed and might in reality have been chronic obstructive pulmonary disease (COPD) showed comparable results. CONCLUSIONS: Under conditions of everyday clinical practice, the addition of montelukast to ICS/FC and good adherence to therapy increased the likelihood of achieving better asthma control at the follow-up visit, while older age and more severe asthma significantly decreased it.

KW - acetates

KW - adult

KW - anti-asthmatic agents

KW - asthma

KW - cohort studies

KW - female

KW - humans

KW - male

KW - middle aged

KW - quinolines

KW - Switzerland

U2 - 10.1185/03007990903224125

DO - 10.1185/03007990903224125

M3 - Article

VL - 25

SP - 2549

EP - 2555

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 10

ER -